Published in Clinical Oncology Week, November 6th, 2006
Study 1: Scientists discovered small molecule integrin alpha(V)beta(3) antagonists with potential anticancer properties.
"Integrin alpha(v)beta(3) has been implicated in multiple aspects of tumor progression and metastasis. Many tumors have high expression of alpha(v)beta(3) that correlates with tumor progression. Therefore, alpha(v)beta(3) receptor is an excellent target for drug design and delivery," researchers in the United States reported.
"We have discovered a series of novel alpha(v)beta(3) antagonists utilizing common feature pharmacophore...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.